Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125374521 | 12537452 | 1 | I | 20160606 | 20160628 | 20160707 | 20160707 | EXP | FR-TEVA-673127ISR | TEVA | 27.81 | YR | M | Y | 0.00000 | 20160707 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125374521 | 12537452 | 1 | PS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; FIRST COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 2 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; SECOND COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 3 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; THIRD COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 4 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; FOURTH COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 5 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; FIFTH COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 6 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MILLIGRAM DAILY; SIXTH COURSE | U | 63097 | 150 | MG | QD | ||||||
| 125374521 | 12537452 | 7 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; FIRST COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 8 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; SECOND COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 9 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; THIRD COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 10 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; FOURTH COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 11 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; FIFTH COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 12 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MILLIGRAM DAILY; SIXTH COURSE | U | 5J271M5 | 0 | 10000 | MG | QD | |||||
| 125374521 | 12537452 | 13 | SS | ZOPHREN 2 mg/ml | ONDANSETRON | 1 | Intravenous (not otherwise specified) | 8 MILLIGRAM DAILY; FIRST COURSE | U | 0 | 8 | MG | SOLUTION FOR INJECTION | QD | |||||
| 125374521 | 12537452 | 14 | SS | METHYLPREDNISOLONE MYLAN 20 MG | METHYLPREDNISOLONE | 1 | Intravenous (not otherwise specified) | 80 MILLIGRAM DAILY; 1ST COURSE | U | 0 | 80 | MG | POWDER FOR INJECTION | QD | |||||
| 125374521 | 12537452 | 15 | SS | MESNA EG | MESNA | 1 | Intravenous (not otherwise specified) | U | 0 | 5000 | MG/M**2 | ||||||||
| 125374521 | 12537452 | 16 | C | EMEND | APREPITANT | 1 | Oral | 80 MILLIGRAM DAILY; | 0 | 80 | MG | CAPSULE | QD | ||||||
| 125374521 | 12537452 | 17 | C | ISENTRESS 400 mg | 2 | Oral | LONG-STANDING TREATMENT | 0 | FILM-COATED TABLET | ||||||||||
| 125374521 | 12537452 | 18 | C | ISENTRESS 400 mg | 2 | Oral | 2 DOSAGE FORMS DAILY; LONG-STANDING TREATMENT | 0 | 1 | DF | FILM-COATED TABLET | BID | |||||||
| 125374521 | 12537452 | 19 | C | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | LONG-STANDING TREATMENT | 0 | FILM-COATED TABLET | |||||||||
| 125374521 | 12537452 | 20 | C | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 200 MILLIGRAM DAILY; LONG-STANDING TREATMENT | 0 | 200 | MG | FILM-COATED TABLET | QD | ||||||
| 125374521 | 12537452 | 21 | C | LYRICA | PREGABALIN | 1 | Oral | 400 MILLIGRAM DAILY; LONG-STANDING TREATMENT | 0 | 200 | MG | BID | |||||||
| 125374521 | 12537452 | 22 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 0 | 1 | DF | TABLET | TIW | |||||||
| 125374521 | 12537452 | 23 | C | PREZISTA | DARUNAVIR ETHANOLATE | 1 | LONG-STANDING TREATMENT | 0 | |||||||||||
| 125374521 | 12537452 | 24 | C | NORVIR | RITONAVIR | 1 | LONG-STANDING TREATMENT | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125374521 | 12537452 | 1 | Sarcoma |
| 125374521 | 12537452 | 7 | Sarcoma |
| 125374521 | 12537452 | 13 | Prophylaxis of nausea and vomiting |
| 125374521 | 12537452 | 14 | Prophylaxis of nausea and vomiting |
| 125374521 | 12537452 | 15 | Prophylaxis |
| 125374521 | 12537452 | 16 | Prophylaxis of nausea and vomiting |
| 125374521 | 12537452 | 17 | Acquired immunodeficiency syndrome |
| 125374521 | 12537452 | 19 | Acquired immunodeficiency syndrome |
| 125374521 | 12537452 | 21 | Pain |
| 125374521 | 12537452 | 22 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125374521 | 12537452 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125374521 | 12537452 | Neutropenia | |
| 125374521 | 12537452 | Somnolence | |
| 125374521 | 12537452 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125374521 | 12537452 | 1 | 20160222 | 20160222 | 0 | |
| 125374521 | 12537452 | 2 | 20160314 | 20160314 | 0 | |
| 125374521 | 12537452 | 3 | 20160404 | 20160404 | 0 | |
| 125374521 | 12537452 | 4 | 20160425 | 20160425 | 0 | |
| 125374521 | 12537452 | 5 | 20160517 | 20160517 | 0 | |
| 125374521 | 12537452 | 6 | 20160606 | 20160606 | 0 | |
| 125374521 | 12537452 | 7 | 20160222 | 20160222 | 0 | |
| 125374521 | 12537452 | 8 | 20160314 | 20160314 | 0 | |
| 125374521 | 12537452 | 9 | 20160404 | 20160404 | 0 | |
| 125374521 | 12537452 | 10 | 20160425 | 20160425 | 0 | |
| 125374521 | 12537452 | 11 | 20160517 | 20160517 | 0 | |
| 125374521 | 12537452 | 12 | 20160606 | 20160606 | 0 | |
| 125374521 | 12537452 | 13 | 20160222 | 0 | ||
| 125374521 | 12537452 | 14 | 20160222 | 0 | ||
| 125374521 | 12537452 | 16 | 20160222 | 0 | ||
| 125374521 | 12537452 | 18 | 20160225 | 0 | ||
| 125374521 | 12537452 | 21 | 201601 | 0 | ||
| 125374521 | 12537452 | 22 | 20160225 | 0 |